作者: Sean Hanniffy , Ursula Wiedermann , Andreas Repa , Annick Mercenier , Catherine Daniel
DOI: 10.1016/S0065-2164(04)56001-X
关键词:
摘要: Publisher Summary This chapter discusses the potential and future opportunities for use of recombinant lactic acid bacteria in human health. It is now clear that sufficient advances genetics (LAB) have made it possible to construct safe LAB-based vaccines are capable eliciting protection against lethal challenge with toxin or a pathogen relevant disease model. There also enhance efficacy LAB through increased antigen expression combined delivery multiple immunogens specific adjuvants. Further insights may be gained direct comparisons strains different persistence survival characteristics immunostimulatory properties immunization routes schedules selected target disease. Genetic engineering clearly has further optimize LAB, define optimal placement dosage regimes clinical settings, their ability deliver pharmaceutical protein.